Protecting Patient Access to Cancer and Complex Therapies Act
The source supplies the latest action, but no lifecycle stage.
Latest action (17 Dec 2024): Referred to the Subcommittee on Health.
What this bill does
H.R. 5391, the Protecting Patient Access to Cancer and Complex Therapies Act, would amend the Social Security Act to require manufacturers of certain drugs and biological products, identified as "selected drugs," to provide rebates to the government. These rebates would be based on the difference between the drug's standard payment amount under Medicare Part B and a negotiated "maximum fair price." The bill would also adjust how beneficiary coinsurance is calculated for these selected drugs, aligning it with the maximum fair price.
This legislation would primarily affect manufacturers of specific drugs covered by Medicare Part B. It would also impact Medicare beneficiaries by potentially altering their cost-sharing for these selected therapies. The bill was introduced in the House of Representatives in September 2023.
As of its introduction, H.R. 5391 was referred to the House Committees on Energy and Commerce and Ways and Means. The bill has not advanced further and did not receive a vote in the previous session of Congress.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
17 Dec 2024
Referred to the Subcommittee on Health.
Common questions
- What does H.R. 5391 do?
- H.R. 5391, the Protecting Patient Access to Cancer and Complex Therapies Act, would amend the Social Security Act to require manufacturers of certain drugs and biological products, identified as "selected drugs," to provide rebates to the government. These rebates would be based on the difference between the drug's standard payment amount under Medicare Part B and a negotiated "maximum fair price." The bill would also adjust how beneficiary coinsurance is calculated for these selected drugs, aligning it with the maximum fair price. This legislation would primarily affect manufacturers of specific drugs covered by Medicare Part B. It would also impact Medicare beneficiaries by potentially altering their cost-sharing for these selected therapies. The bill was introduced in the House of Representatives in September 2023. As of its introduction, H.R. 5391 was referred to the House Committees on Energy and Commerce and Ways and Means. The bill has not advanced further and did not receive a vote in the previous session of Congress.
- Has H.R. 5391 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 5391. Check the latest action and official source below.
- Who sponsored H.R. 5391?
- H.R. 5391 was sponsored by Rep. Burgess, Michael C. [R-TX-26] (R-TX), with 4 cosponsors.
- What's the latest action on H.R. 5391?
- Referred to the Subcommittee on Health. (17 Dec 2024).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Burgess, Michael C. [R-TX-26]
Providers and Payers COMPETE Act
Social Determinants of Health Data Analysis Act of 2021
Advancing Research for Neurological Diseases Act of 2015
Modernizing Laboratory Test Standards for Patients Act of 2011
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.